AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2021
Jan 6, 2021
32407_dirs_2021-01-05_4a1beaab-a45e-4aa4-bbf0-a806dc09516e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2021-01-04
Reporting Person: Nabulsi Azmi (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-04 | Common Stock | S | 4932 | $33.0174 | Disposed | 833268 | Indirect |
| 2020-01-04 | Common Stock | S | 7614 | $33.9332 | Disposed | 825654 | Indirect |
| 2020-01-04 | Common Stock | S | 100 | $34.57 | Disposed | 825554 | Indirect |
| 2020-01-05 | Common Stock | S | 1854 | $33.7694 | Disposed | 823700 | Indirect |
Footnotes
F1: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.50. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.39. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.5 to $34.01. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.